1. Foreword

   • T. J. McElwain

   EditorialNotes Pages: 71 - 71

2. The podophyllotoxin derivatives VP16-213 and VM26

   • Brian F. Issell

   Review Pages: 73 - 80

3. VP16-213 (Etoposide)

   • F. Cavalli

   Review Pages: 81 - 85

4. VM26: Phase I and II studies

   • F. R. Macbeth

   Review Pages: 87 - 91

5. Current development of podophyllotoxins

   • Renzo Canetta
   • Peter Hilgard
   • Luigi Lenaz

   Review Pages: 93 - 98

6. Modification of the pendant ring of podophyllotoxin

   • David C. Ayres
   • Chang Kee Lim

   Articles Pages: 99 - 101

7. VP16-213 and podophyllotoxin

   • John D. Loike

   Articles Pages: 103 - 111

8. Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors

   • Brian F. Issell
   • Claude Tihon
   • M. Elaine Curry

   Articles Pages: 113 - 115

9. A radioimmunoassay for VP16-213 in plasma

   • G. Wynne Aherne
   • Vincent Marks

   Articles Pages: 117 - 121

10. Interaction of VP16-213 with the DNA repair antagonist chloroquine

    • A. M. Arnold
    • J. M. A. Whitehouse

    Articles Pages: 123 - 126

11. Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice

    • Tina Colombo
    • Massimo Broggini
    • Maurizio D'Incalci

    Articles Pages: 127 - 131

12. The clinical pharmacology of VM26 and VP16-213

    • Patrick J. Creaven

    Articles Pages: 133 - 140

13. Pharmacokinetics of VP16-213 given by different administration methods

    • M. D'Incalci
    • P. Farina
    • F. Cavalli

    Articles Pages: 141 - 145

14. Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer

    • William E. Evans
    • Joseph A. Sinkule
    • Gaston Rivera

    Articles Pages: 147 - 150

15. Combination chemotherapy of the epipodophyllotoxin derivatives, Teniposide and Etoposide

    • Larry M. Allen
    • Francisco Tejada
    • Staffan Nordqvist

    Articles Pages: 151 - 156

16. A phase I trial of continuous infusion VP16-213 (Etoposide)

    • Joseph Aisner
    • David A. Van Echo
    • Peter H. Wiernik

    Articles Pages: 157 - 160

17. Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute nonlymphocytic leukemia

    • A. Thomas Look
    • Gary V. Dahl
    • Alvin M. Mauer

    Articles Pages: 161 - 167

18. VM26 therapy in children with drug-refractory lymphocytic leukemia

    • Gaston Rivera
    • Gary V. Dahl
    • J. V. Simone

    Articles Pages: 169 - 172

19. VM26 in malignant hematological diseases

    • Umberto Tirelli
    • Antonino Carbone
    • Eligio Grigoletto

    Articles Pages: 173 - 174

20. Etoposide as a single agent in relapsed advanced lymphomas

    • R. E. Taylor
    • T. J. McElwain
    • M. J. Peckham

    Articles Pages: 175 - 177

21. Epipodophyllotoxin (VP16-213) in small cell carcinoma of the bronchus resistant to initial combination chemotherapy

    • P. G. Harper
    • M. B. Dally
    • R. L. Souhami

    Articles Pages: 179 - 180

22. Treatment of small cell lung cancer with a combination of VP16-213 and cyclophosphamide with cisplatin or radiotherapy

    • H. Cortés Funes
    • P. Dominguez
    • C. Mendiola

    Articles Pages: 181 - 186

23. Doxorubicin, cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer

    • Joseph Aisner
    • Margaret Whitacre
    • Peter H. Wiernik

    Articles Pages: 187 - 193

24. Vincristine, adriamycin, cyclophosphamide, and etoposide (VP16-213) in small-cell anaplastic carcinoma of the lung

    • F. E. von Eyben
    • Å. Arwidi
    • L. Tennvall

    Articles Pages: 195 - 197

25. Chemotherapy combination with cyclophosphamide (CTX) adriamycin (ADM), vincristine (VCR), and VP16-213 in small cell carcinoma of the lung (SCCL)

    • J. M. Gracia
    • A. Jimenez

    Articles Pages: 199 - 201

26. VP16-213 combined with cis-platinum (CDDP) in the treatment of small cell carcinoma of the lung (SCLC)

    • P. A. Madrigal
    • G. P. Manga
    • R. Garcia Gomez

    Articles Pages: 203 - 204

27. Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)

    • Robert Chapman
    • Loretta Itri
    • Robert Golbey

    Articles Pages: 205 - 207

28. VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma

    • L. Morasca
    • S. Marsoni
    • R. Scapaticci

    Articles Pages: 209 - 210

29. The role of VP16-213 (Etoposide; NSC-141540) in gestational choriocarcinoma

    • Edward S. Newlands
    • Kenneth D. Bagshawe

    Articles Pages: 211 - 214

30. VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasms

    • J. Mortimer
    • R. M. Bukowski
    • R. B. Livingston

    Articles Pages: 215 - 218

31. Reversal of recurrent laryngeal nerve palsy following VP16-213 combination therapy in a patient with metastatic teratoma of the testis

    • Eileen D. Rubery

    Articles Pages: 219 - 221

32. Phase II study of VP16-213 (Etoposide) in refractory metastatic breast carcinoma

    • F. C. Schell
    • H. Y. Yap
    • L. Esparza

    Articles Pages: 223 - 225

33. Mitomycin-C, VP16-213 combination as third line chemotherapy in advanced breast cancer

    • G. Perez Manga
    • P. L. Madrigal Alonso
    • H. Alburquerque Carbuccia

    Articles Pages: 227 - 229

34. Adriamycin and VP16-213 combination treatment for breast cancer previously treated by the CMF regimen

    • G. Perez Manga
    • P. Madrigal Alonso
    • H. Alburquerque Carbuccia

    Articles Pages: 231 - 233

35. Abstract

    Abstract Pages: 235 - 243